Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
OTTAWA, ON, April 29, 2025 /CNW/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced the completion of ISO 10993 biocompatibility testing and human skin safety testing for its future product family, CelluJuve ®, a series of next-generation dermal fillers.
CelluJuve ® is a cellulose-based dermal filler solution being developed to provide structural support for soft tissue augmentation and rejuvenation.
"The successful completion of ISO 10993 testing is a pivotal moment for Spiderwort in our advancement toward clinical trials," said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc. "These results help validate our innovative biotechnology platform that transforms cellulose into a medical-grade product."
ISO 10993 testing is a key prerequisite for entering human clinical trials. As a complement to ISO 10993 requirements, Spiderwort Biotechnologies Inc. performed skin prick and patch testing in human subjects to further validate biocompatibility. The comprehensive testing demonstrated in non-clinical models that CelluJuve ® is:
Non-toxic, non-sensitizing, and non-mutagenic
Classified as a non-irritant and non-sensitizing for a diverse range of human skin types, as verified through additional human skin prick and patch testing
Highly biocompatible and stable
"These results represent years of technical development in transforming cellulose-based materials into medical-grade solutions," Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc., "Our team has fundamentally reimagined what's possible in biomaterials, proving we can leverage plant structures in ways that are not only compatible with human tissue but offer unique advantages over traditional options. This milestone helps validate our approach and moves us closer to redefining what's possible in regenerative medicine."
Throughout the assessments, Spiderwort Biotechnologies Inc. placed significant emphasis on ensuring diversity in its testing protocols. This approach ensures CelluJuve ® has the potential to benefit all skin tones, reflecting Spiderwort Biotechnologies Inc.'s commitment to inclusive development practices.
"As a clinician focused on aesthetic outcomes and patient safety, I'm impressed with CelluJuve's biocompatibility profile," Dr. Jason Bloom, MD, FACS, member of Spiderwort's Clinical Advisory Board and renowned facial plastic surgeon, "The non-irritant classification and human testing results suggest CelluJuve ® could offer a compelling alternative in the dermal filler space. Physicians and patients increasingly seek new and innovative options with favorable safety profiles, and these test results position CelluJuve ® to potentially address that growing demand while offering unique structural properties for tissue augmentation and rejuvenation."
Construction of Spiderwort's state-of-the-art ISO 5 cleanroom facility, announced earlier this year, has been instrumental in achieving these results, reinforcing the company's ability to transform raw cellulose materials into medical devices that meet the stringent standards necessary for human use.
CelluJuve ® is a device under development. It is not approved by Health Canada or the U.S. Food and Drug Administration, and it is not available for sale. The safety and effectiveness of CelluJuve ® in humans has not been established. For more information about Spiderwort Biotechnologies and CelluJuve ®, please visit https://spiderwortbio.com/product/cellujuve/.
About Spiderwort Biotechnologies Inc.
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort's biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 days ago
- Cision Canada
MEDIA ADVISORY: Baycrest Experts Available During AAIC® 2025 in Toronto
TORONTO, July 25, 2025 /CNW/ - From July 27 to 31, Toronto hosts the Alzheimer's Association International Conference ® 2025 (AAIC ®), the world's largest forum for dementia research. With Canada in the spotlight, Baycrest is recognized globally for its leadership in aging and brain health. Our scientists and experts are participating in the conference and available to support your coverage. This international gathering offers a timely opportunity to explore the growing impact of dementia on families, economies and health care systems, along with the latest advances in prevention, care, treatment and research. Dr. Howard Chertkow Scientific Director, Baycrest's Kimel Family Centre for Brain Health & Wellness Scientific Director, Canadian Consortium on Neurodegeneration in Aging (CCNA) Dr. Chertkow is a member of the AAIC Scientific Program Committee and one of Canada's most respected dementia researchers. He is available to speak on topics including dementia detection, prevention, treatment and Canada's role in the global research landscape. More Baycrest Experts You Can Speak With Dr. Adriana Shnall, Program Director, Baycrest Koschitzky Centre for Innovations in Caregiving, can speak to innovative tools supporting dementia caregivers, including those in rural and underserved communities. At AAIC, she is co-presenting on the use of virtual reality, AI and other strategies to better support families in community and long-term care settings. Dr. Allison Sekuler, President & Chief Scientist, Baycrest Academy for Research and Education is available to speak on the rising prevalence of dementia in Canada and its impact on individuals, families and the healthcare system. Dr. Nicole Anderson, Associate Scientific Director, Baycrest's Kimel Family Centre for Brain Health & Wellness, can discuss the latest in dementia prevention research, including evidence that nearly half of all cases may be preventable. Baycrest combines world-class care with cutting-edge research to help shape the future of aging and brain health. If you are working on AAIC-related coverage or broader dementia stories, our experts are available for interviews throughout the conference. Throughout the week, we will share updates with media highlighting key topics, research developments and expert perspectives from Baycrest. Please contact Natasha Nacevski-Laird, Media Relations Specialist at Baycrest, to schedule an interview. About Baycrest At Baycrest, our vision is a world where every older person lives with purpose, fulfilment and dignity. Baycrest is a global leader in aging and brain health innovation, with over 105 years of expertise in seniors' care and cutting-edge research. Baycrest has been Designated with Exemplary Status by Accreditation Canada, and drives industry-leading care and safety outcomes. As the home of the Centre for Aging + Brain Health Innovation (CABHI) powered by Baycrest, the Baycrest Academy for Research and Education (BARE) and the Canadian Consortium on Neurodegeneration in Aging, Baycrest is at the forefront of dementia research. Affiliated with the University of Toronto, Baycrest's training programs shape the future of care globally, while Baycrest Global Solutions extends its expertise to senior living and healthcare internationally. For more information, visit:
Cision Canada
3 days ago
- Cision Canada
CIBC Recognized as a Leading Workplace for Disability Inclusion Français
TORONTO, July 25, 2025 /CNW/ - CIBC announced today it has been recognized as a Best Place to Work for Disability Inclusion after earning a top score on the 2025 Canada Disability Index®. This recognition underscores CIBC's ongoing commitment to matching talent to opportunity and promoting a workplace where all team members can flourish. The Disability Index® is a leading third-party benchmarking tool for workplace disability inclusion, and measures performance across key areas such as culture and leadership, enterprise-wide access, employment practices, community engagement, and supplier inclusion. "At CIBC, inclusion is the cornerstone of our bank's culture. Building a workforce that reflects the clients and communities we serve allows for unique perspectives, experiences, and drives innovation," said Sandy Sharman, Group Head, People, Culture and Brand, CIBC. "This recognition reinforces our commitment to supporting our team members and empowering them to achieve their ambitions." By achieving this distinction, CIBC joins hundreds of global organizations dedicated to advancing accessibility and supporting 1.3 billion people with disabilities worldwide 1. To learn more about our commitments, visit Accessibility at CIBC. CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at
Cision Canada
3 days ago
- Cision Canada
Shoppers Foundation for Women's Health launches in-store period product donation drive to promote menstrual equity
Support local women's shelters and food banks via the Pad It Forward campaign TORONTO, July 25, 2025 /CNW/ - Shoppers Foundation for Women's Health™ is inviting Canadians to join them in their fight for menstrual equity by donating pads, tampons, period underwear and menstrual cups at their local Shoppers Drug Mart® store as part of its new Pad it forward donation campaign. "We know that 17% of people in Canada have experienced period poverty 1 – unable to access or afford the menstrual products they need. And this number jumps to 1 in 4 among people living in lower-income households," says Paulette Minard, Director of Community Investment and Shoppers Foundation for Women's Health™. "Together with Shoppers Drug Mart, the Foundation is taking action to change this reality, helping to make period products more accessible to those who need them." Since 2022, Shoppers Foundation for Women's Health™ has committed to donate more than 69 million period care products collectively to schools and community organizations in Ontario, Manitoba, Newfoundland and Saskatchewan so people who menstruate can access necessary care while continuing to attend class and other activities. In this same time period, the Foundation has donated more than $2.6 million in funds and supplies to expand access to menstrual products and care through partners like Moon Time Connections – Canada's only national Indigenous-led period equity organization. "Moon Time Connections is incredibly grateful to Shoppers Foundation for Women's Health™ for partnering with us to ensure we can continue reaching remote and northern Indigenous menstruators with much-needed support," shares Nicole White, Founder of Moon Time Connections (MTC). "Funding provided by the Foundation to MTC allows us to continue offering our Moon Time Facilitator training program, which Indigenizes menstrual education and empowers community with vital and culturally relevant resources, while also supporting with product distribution." Donations bins for this in-store program will be visible near the checkout area in stores nationwide, with all donated products going to one of more than 300 local women's shelters or community food banks. Donations will be accepted from July 26 to August 8. Visit your local Shoppers Drug Mart® or Pharmaprix® store to donate and learn more about Pad it forward. About Shoppers Foundation for Women's Health™ Shoppers Foundation for Women's Health™ – the charitable arm of Shoppers Drug Mart® – is committed to helping Canadian women lead healthier lives, by making care more equitable and accessible. The Foundation will invest $50M by 2026 to address some of the most pressing health inequities facing women, including lack of representation in health research, barriers to accessing mental healthcare, and the urgent consequences women disproportionately face due to poverty and domestic violence. Learn more at About Shoppers Drug Mart Inc. Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart® (Pharmaprix® in Québec). With more than 1,350 Shoppers Drug Mart® and Pharmaprix® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. Shoppers Drug Mart® is an independent operating division of Loblaw Companies Limited.
